Analyst firms · Oppenheimer · EDIT
Oppenheimer EDIT price target and rating history
Editas Medicine Inc. (EDIT) · Health Care
Oppenheimer rates Editas Medicine Inc. (EDIT) Perform with a $12 price target, as of its latest action on Nov 18, 2022. It has published 3 rating actions on EDIT since September 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.
- Current rating
- Perform
- Price target
- $12
- Median target, all firms
- $6
- Actions on EDIT
- 3
Oppenheimer price target on EDIT
Every Oppenheimer rating on EDIT
- Nov 18, 2022
- Feb 25, 2022
- Sep 10, 2021
How other firms rate EDIT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Overweight | $6 | Oct 8, 2026 |
| Guggenheim | Buy | $5 | Sep 23, 2026 |
| Ladenburg Thalmann | Buy | $6 | Aug 18, 2026 |
Questions about Oppenheimer and EDIT
- What is Oppenheimer's price target for EDIT?
- Oppenheimer's latest stated price target for Editas Medicine Inc. (EDIT) is $12, from its action on Nov 18, 2022.
- What is Oppenheimer's rating on EDIT?
- Oppenheimer rates EDIT Perform, a neutral rating, as of Nov 18, 2022.
- When did Oppenheimer last change its view on EDIT?
- On Nov 18, 2022, Oppenheimer downgrades to Perform from Outperform, price target $28 to $12.
- How does Oppenheimer's EDIT target compare with other analysts?
- Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.
More EDIT rating histories
All Oppenheimer ratingsEDIT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.